Technology

A novel approach to CRISPR

EXCISION

Approach

Dual gRNAs excise large sections of viral DNA, eliminating viral escape and reproduction. The result is curative.

Large Deletion,

No Probability of Escape

DISCOVERY

Platform

Excision's platform enables in silico design of probes to analyze on- and off-target effects and integrates computational methods to design the most effective guide RNAs.

We are transforming drug discovery and target validation from traditional to digital.

THERAPEUTIC

Pipeline

Pre-Clinical In Vitro Studies

Pre-Clinical In Vivo Studies

IND Filing

EBT-101 HIV multiplex Cas9 dual gRNA Therapeutic

2020

EBT-103 PML/JCV Cas9 triplet gRNA T-antigen Therapeutic

Q1 2022

EBT-104 HSV Cas9 dual gRNA Therapeutic

Q4 2022

EBT-107 HBV CasX or Y dual gRNA Therapeutic

Q3 2023

EBT-201 COVID-19 Treatment & Prevention: CasY, Cas9, Cas13a

In Development

988 Market Street
San Francisco, CA 94102
USA

1755 N. 13th Street #274
Philadelphia, PA 19122
USA

© 2020 Excision BioTherapeutics. All Rights Reserved.